A 52-year-old man with a 15-year history of COPD presents to the outpatient clinic with persistent dyspnea on exertion despite being on inhaled salbutamol as needed. His FEV₁ is 45% predicted. On examination, he has mild peripheral edema and elevated JVP. Chest X-ray shows hyperinflation. His current medications include salbutamol inhaler (2–3 times daily) and occasional oral theophylline. The physician decides to add a long-acting bronchodilator to his regimen. Which of the following is the most appropriate choice for maintenance therapy in this patient?

Explanation

## Rationale for Long-Acting Bronchodilator Selection **Key Point:** In moderate-to-severe COPD (FEV₁ 45% predicted), long-acting bronchodilators (LABAs or LAMAs) are indicated for maintenance therapy to reduce symptoms and exacerbations. ### Why Salmeterol is Correct Salmeterol is a long-acting beta-2 agonist (LABA) with a duration of action of 12 hours, making it ideal for twice-daily maintenance dosing. In this patient: - FEV₁ 45% predicted indicates moderate-to-severe airflow obstruction - Persistent symptoms despite short-acting salbutamol indicate need for maintenance therapy - LABAs provide sustained bronchodilation and reduce exacerbation frequency - Salmeterol has a lipophilic tail that deposits in lung tissue, providing prolonged action [cite:KD Tripathi 8e Ch 27] **High-Yield:** GOLD guidelines recommend LABAs or LAMAs as first-line maintenance therapy in symptomatic COPD patients with FEV₁ < 50% predicted. ### Mechanism of Action Salmeterol binds to beta-2 adrenergic receptors on airway smooth muscle, increasing intracellular cAMP and causing smooth muscle relaxation. The lipophilic side chain allows depot formation in lung tissue, explaining its prolonged action. ### Clinical Considerations in This Patient | Feature | Salmeterol | Ipratropium | Terbutaline | |---------|-----------|------------|------------| | Duration | 12 hours | 6–8 hours | 4–6 hours | | Maintenance use | Yes | Yes (but short-acting) | No (rescue only) | | Onset | 10–20 min | 30–60 min | 5–15 min | | Edema risk | Low | None | None | **Clinical Pearl:** The patient's mild peripheral edema and elevated JVP suggest possible cor pulmonale from chronic hypoxia. While beta-2 agonists can theoretically worsen fluid retention, salmeterol's maintenance benefit outweighs this risk in COPD. The edema is likely from right heart strain, not drug-induced. **Warning:** Never use LABAs as monotherapy in asthma (increased mortality risk); always combine with inhaled corticosteroids. In COPD, LABAs can be used alone. ### Alternative Long-Acting Options Ipratropium (short-acting anticholinergic) could be added but is not ideal as monotherapy because: - Requires 3–4 times daily dosing - Slower onset (30–60 min) compared to salmeterol - Anticholinergics are typically second-line or added to LABAs A combination of LABA + LAMA (e.g., salmeterol + tiotropium) would be even more effective but the question asks for a single agent.